Boston Scientific is trading 7.2% down at $42.75 as cautious Q3 guidance and a major restructuring plan overshadow a Q2 earnings beat.
- While revenue and EPS topped estimates led by robust Cardiovascular growth, management’s 3%–5% Q3 organic growth outlook fell short of expectations.
- The company narrowed its full-year EPS range and initiated a margin-defense restructuring plan, driving a negative reaction and profit-taking.